Annals of Surgical Oncology

, Volume 16, Issue 2, pp 385–394 | Cite as

A Phase I Study of Hyperthermic Isolated Hepatic Perfusion with Oxaliplatin in the Treatment of Unresectable Liver Metastases from Colorectal Cancer

  • Herbert J. ZehIII
  • Charles K. Brown
  • Matthew P. Holtzman
  • Merrill J. Egorin
  • Julianne L. Holleran
  • Douglas M. Potter
  • David L. Bartlett
Hepatobiliary and Pancreatic Tumors


Isolated hepatic perfusion (IHP) is a proven approach for regional delivery of chemotherapy in patients with unresectable primary and metastatic tumors of the liver. Most trials of IHP have utilized melphalan as the active drug in the perfusate. We performed a phase I trial to evaluate the efficacy, safety, and maximum tolerated dose (MTD) of oxaliplatin delivered by hyperthermic isolated hepatic perfusion. A phase I dose-escalation trial of hyperthermic IHP with oxaliplatin in patients with unresectable metastatic colorectal cancer scheduled to undergo placement of a hepatic arterial infusion (HAI) pump was carried out. Thirteen patients were enrolled between November 2003 and September 2006. Dose-limiting veno-occlusive disease was observed at 60 mg/m2. At the MTD of 40 mg/m2 only minor transient liver dysfunction was observed. Ultrafilterable platinum area under the curve and maximum concentration delivered by IHP increased nonlinearly with dose as did platinum concentrations in liver biopsies obtained at the end of the 60 min IHP. Seventy-seven percent of patients had a >50% decrease in serum carcinoembryonic antigen (CEA) after IHP. The overall response rate to the combined IHP and HAI therapy was 66%. One patient had a durable complete response (>4 years). We conclude that hyperthermic IHP with oxaliplatin was safe and feasible at a dose of 40 mg/m2. The ability to obtain complete vascular isolation with open IHP was confirmed. The response rate in this small phase I study was encouraging.


  1. 1.
    American Cancer Society. Facts and figures 2007. Atlanta, GA; 2007.Google Scholar
  2. 2.
    Lahr CJ, Soong SJ, Cloud G, Smith JW, Urist MM, Balch CM. A multifactorial analysis of prognostic factors in patients with liver metastases from colorectal carcinoma. J Clin Oncol. 1983;1(11):720–6.PubMedGoogle Scholar
  3. 3.
    Rougier P, Milan C, Lazorthes F, Fourtanier G, Partensky C, Baumel H, et al. Prospective study of prognostic factors in patients with unresected hepatic metastases from colorectal cancer. Br J Surg. 1995;82:1397–400.PubMedCrossRefGoogle Scholar
  4. 4.
    Choti MA, Bulkley GB. Management of hepatic metastases. Liver Transplant Surg. 1999;5:65–80.CrossRefGoogle Scholar
  5. 5.
    Manfredi S, Lepage C, Hatem C, Coatmeur O, Faivre J, Bouvier AM. Epidemiology and management of liver metastases from colorectal cancer. Ann Surg. 2006;244(2):254–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Kato T, Yasui K, Hirai T, Kanemitsu Y, Mori T, Sugihara K, et al. Therapeutic results for hepatic metastasis of colorectal cancer with special reference to effectiveness of hepatectomy: analysis of prognostic factors for 763 cases recorded at 18 institutions. Dis Colon Rectum. 2003;46(10 Suppl):S22–31.PubMedGoogle Scholar
  7. 7.
    Ercolani G, Grazi GL, Ravaioli M, Cescon M, Gardini A, Varotti G, et al. Liver resection for multiple colorectal metastases: influence of parenchymal involvement and total tumor volume, vs number or location on long-term survival. Arch Surg. 2002;137(10):1187–92.PubMedCrossRefGoogle Scholar
  8. 8.
    Choti MA, Sitzmann JV, Tiburi MF, Sumetchotimetha W, Rangsin R, Schulick RD, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg. 2002;235(6):759–66.PubMedCrossRefGoogle Scholar
  9. 9.
    Nesbitt C, Glendinning RJ, Byrne C, Poston GJ. Factors that influence treatment strategies in advanced colorectal cancer. Eur J Surg Oncol. 2007;33(Suppl 2):S88–94.PubMedGoogle Scholar
  10. 10.
    Kemeny N. Management of liver metastases from colorectal cancer. Oncology. 2006;20(10):1161–76, 1179.Google Scholar
  11. 11.
    Wicherts DA, de Haas RJ, Adam R. Bringing unresectable liver disease to resection with curative intent. Eur J Surg Oncol. 2007;33(Suppl 2):S42–51.PubMedGoogle Scholar
  12. 12.
    Chun YS, Vauthey JN. Extending the frontiers of resectability in advanced colorectal cancer. Eur J Surg Oncol. 2007;33(Suppl 2):S52–8.PubMedGoogle Scholar
  13. 13.
    Bismuth H, Adam R, Lévi F, Farabos C, Waechter F, Castaing D. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg. 1996;224(4):509–22.Google Scholar
  14. 14.
    Abdalla EK, Adam R, Bilchik AJ, Jaeck D, Vauthey JN, Mahvi D. Improving resectability of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol. 2006;13(10):1271–80.PubMedCrossRefGoogle Scholar
  15. 15.
    Alexander HR, Libutti SK, Bartlett DL, Puhlmann M, Fraker DL, Bachenheimer LC. A phase I-II study of isolated hepatic perfusion using melphalan with or without tumor necrosis factor for patients with ocular melanoma metastatic to liver. Clin Cancer Res. 2000;6(8):3062–70PubMedGoogle Scholar
  16. 16.
    Alexander HR, Bartlett DL, Libutti SK. Isolated hepatic perfusion: A potentially effective treatment for patients with metastatic or primary cancers confined to the liver. Cancer J Sci Am. 1998;4:2–11.PubMedGoogle Scholar
  17. 17.
    Alexander HR, Bartlett DL, Libutti SK, Fraker DL, Moser T, Rosenberg SA. Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. J Clin Oncol. 1998;16:1479–89.PubMedGoogle Scholar
  18. 18.
    Alexander HR, Bartlett DL, Fraker DL, Libutti SK, Moser T, Rosenberg SA. Results of a Phase II study of isolated hepatic perfusion (IHP) with tumor necrosis factor (TNF) and melphalan for unresectable primary or metastatic cancer confined to the liver. Proc Soc Surg Oncol. 1997;6:8. Ref Type: Abstract.Google Scholar
  19. 19.
    Alexander HR Jr, Libutti SK, Pingpank JF, Bartlett DL, Helsabeck C, Beresneva T. Isolated hepatic perfusion for the treatment of patients with colorectal cancer liver metastases after irinotecan-based therapy. Ann Surg Oncol. 2005;12(2):138–44.PubMedCrossRefGoogle Scholar
  20. 20.
    Bartlett DL, Libutti SK, Figg WD, Fraker DL, Alexander HR. Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer. Surgery. 2001;129(2):176–87.PubMedCrossRefGoogle Scholar
  21. 21.
    Bartlett DL, Alexander HR Jr. Isolated hepatic perfusion. In: Steele GD Jr, Phillips TL, Chabner BA, editors. Hepatobiliary cancer. Canada: B.C. Decker; 2001. p. 245–53.Google Scholar
  22. 22.
    de Wilt JH, van EB, Verhoef C, Eggermont AM. Isolated hepatic perfusion: experimental evidence and clinical utility. Surg Clin North Am. 2004;84(2):627–41.PubMedCrossRefGoogle Scholar
  23. 23.
    Lise M, Pilati P, Da PP, Mocellin S, Ori C, Casara D, et al. Hyperthermic isolated liver perfusion for unresectable liver cancers: pilot study. J Chemother. 2004;16(Suppl 5):37–9.PubMedGoogle Scholar
  24. 24.
    Grover AC, Libutti SK, Pingpank JF, Helsabeck C, Beresnev T, Alexander HR Jr Isolated hepatic perfusion for the treatment of patients with advanced liver metastases from pancreatic and gastrointestinal neuroendocrine neoplasms. Surgery. 2004;136(6):1176–82.PubMedCrossRefGoogle Scholar
  25. 25.
    Alexander HR, Libutti SK, Bartlett DL, Puhlmann M, Fraker DL, Bachenheimer LC. A Phase I-II study of isolated hepatic perfusion using melphalan with or without tumor necrosis factor for patients with ocular melanoma metastatic to liver. Clin Cancer Res. 2000;6:3062–70.PubMedGoogle Scholar
  26. 26.
    Alexander HR Jr, Bartlett DL, Libutti SK. National Cancer Institute experience with regional therapy for unresectable primary and metastatic cancer of the liver or peritoneal cavity. In: Markman M, editor. Current clinical oncology: regional chemotherapy: clinical research and practice. Totowa, NJ: Humana; 2000. p. 127–50.Google Scholar
  27. 27.
    Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2002;92(3):205–16.Google Scholar
  28. 28.
    Erkmen K, Egorin MJ, Reyno LM, Morgan R Jr, Doroshow JH. Effects of storage on the binding of carboplatin to plasma proteins. Cancer Chemother Pharmacol. 1995;35(3):254–6.PubMedCrossRefGoogle Scholar
  29. 29.
    Zamboni WC, Gervais AC, Egorin MJ, Schellens JH, Hamburger DR, Delauter BJ, et al. Inter- and intratumoral disposition of platinum in solid tumors after administration of cisplatin. Clin Cancer Res. 2002;8(9):2992–9.PubMedGoogle Scholar
  30. 30.
    Kho Y, Jansman FG, Prins NH, Neef C, Brouwers Jr Population pharmacokinetics of oxaliplatin (85 mg/m2) in combination with 5-fluorouracil in patients with advanced colorectal cancer. Ther Drug Monit. 2006;28(2):206–11.PubMedCrossRefGoogle Scholar
  31. 31.
    Graham MA, Lockwood GF, Greenslade D, Brienza S, Bayssas M, Gamelin E. Clinical pharmacokinetics of oxaliplatin: a critical review. Clin Cancer Res. 2000;6(4):1205–18.PubMedGoogle Scholar
  32. 32.
    Wasserman E, Cuvier C, Lokiec F, Goldwasser F, Kalla S, Mery-Mignard D, et al. Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: results of two independent phase I studies with pharmacokinetics. J Clin Oncol. 1999;17(6):1751–9.PubMedGoogle Scholar
  33. 33.
    Cho HK, Lee ES, Lee JW, Park JK, Kang JH, Lee KS, et al. Clinical pharmacokinetics of oxaliplatin and 5-fluorouracil administered in combination with leucovorin in Korean patients with advanced colorectal cancer. J Cancer Res Clin Oncol. 2006;132(5):320–6.PubMedCrossRefGoogle Scholar
  34. 34.
    Takimoto CH, Graham MA, Lockwood G, Ng CM, Goetz A, Greenslade D, et al. Oxaliplatin pharmacokinetics and pharmacodynamics in adult cancer patients with impaired renal function. Clin Cancer Res. 2007;13(16):4832–9.PubMedCrossRefGoogle Scholar
  35. 35.
    Synold TW, Takimoto CH, Doroshow JH, Gandara D, Mani S, Remick SC, et al. Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: a National Cancer Institute Organ Dysfunction Working Group study. Clin Cancer Res. 2007;13(12):3660–6.PubMedCrossRefGoogle Scholar
  36. 36.
    Kern W, Braess J, Bottger B, Kaufmann CC, Hiddemann W, Schleyer E. Oxaliplatin pharmacokinetics during a four-hour infusion. Clin Cancer Res. 1999;5(4):761–5.PubMedGoogle Scholar
  37. 37.
    Massari C, Brienza S, Rotarski M, Gastiaburu J, Misset JL, Cupissol D, et al. Pharmacokinetics of oxaliplatin in patients with normal versus impaired renal function. Cancer Chemother Pharmacol. 2000;45(2):157–64.PubMedCrossRefGoogle Scholar
  38. 38.
    Raymond E, Chaney SG, Taamma A, Cvitkovic E. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol. 1998;9(10):1053–71.PubMedCrossRefGoogle Scholar
  39. 39.
    Kern W, Beckert B, Lang N, Stemmler J, Beykirch M, Stein J, et al. Phase I and pharmacokinetic study of hepatic arterial infusion with oxaliplatin in combination with folinic acid and 5-fluorouracil in patients with hepatic metastases from colorectal cancer. Ann Oncol. 2001;12(5):599–603.PubMedCrossRefGoogle Scholar
  40. 40.
    Fiorentini G, Rossi S, Dentico P, Meucci F, Bonechi F, Bernardeschi P, et al. Oxaliplatin hepatic arterial infusion chemotherapy for hepatic metastases from colorectal cancer: a phase I–II clinical study. Anticancer Res. 2004;24(3b):2093–6.PubMedGoogle Scholar
  41. 41.
    Guthoff I, Lotspeich E, Fester C, Wallin I, Schatz M, Ehrsson H, et al. Hepatic artery infusion using oxaliplatin in combination with 5-fluorouracil, folinic acid and mitomycin C: oxaliplatin pharmacokinetics and feasibility. Anticancer Res. 2003;23(6):5203–8.PubMedGoogle Scholar
  42. 42.
    Mancuso A, Giuliani R, Accettura C, Palma M, D’Auria G, Cecere F, et al. Hepatic arterial continuous infusion (HACI) of oxaliplatin in patients with unresectable liver metastases from colorectal cancer. Anticancer Res. 2003;23(2C):1917–22.PubMedGoogle Scholar
  43. 43.
    Meyer L, Hildebrandt B, Riess H. 5-fluorouracil, folinic acid and oxaliplatin administered via hepatic arterial infusion as regional second-line therapy for advanced colorectal cancer. Oncology. 2003;64(4):473–4.PubMedCrossRefGoogle Scholar
  44. 44.
    Rietbroek RC, van de Vaart PJ, Haveman J, Blommaert FA, Geerdink A, Bakker PJ, et al. Hyperthermia enhances the cytotoxicity and platinum-DNA adduct formation of lobaplatin and oxaliplatin in cultured SW 1573 cells. J Cancer Res Clin Oncol. 1997;123(1):6–12.PubMedCrossRefGoogle Scholar
  45. 45.
    Elias D, Bonnay M, Puizillou JM, Antoun S, Demirdjian S, El OA, et al. Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. Ann Oncol. 2002;13(2):267–72.PubMedCrossRefGoogle Scholar
  46. 46.
    van Iersel LB, Verlaan MR, Vahrmeijer AL, van Persijn van Meerten EL, Tijl FG, Sparidans RW, et al. Hepatic artery infusion of high-dose melphalan at reduced flow during isolated hepatic perfusion for the treatment of colorectal metastases confined to the liver: a clinical and pharmacologic evaluation. Eur J Surg Oncol. 2007;33(7):874–81.Google Scholar
  47. 47.
    Mocellin S, Pilati P, Da PP, Forlin M, Corazzina S, Rossi CR, et al. Correlation between melphalan pharmacokinetics and hepatic toxicity following hyperthermic isolated liver perfusion for unresectable metastatic disease. Ann Surg Oncol. 2007;14(2):802–9.PubMedCrossRefGoogle Scholar
  48. 48.
    Yoshizumi T, Gondolesi GE, Bodian CA, Jeon H, Schwartz ME, Fishbein TM, et al. A simple new formula to assess liver weight. Transplant Proc. 2003;35(4):1415–20.PubMedCrossRefGoogle Scholar
  49. 49.
    Vauthey JN, Abdalla EK, Doherty DA, Gertsch P, Fenstermacher MJ, Loyer EM, et al. Body surface area and body weight predict total liver volume in Western adults. Liver Transpl. 2002;8(3):233–40.PubMedCrossRefGoogle Scholar
  50. 50.
    Takimoto CH, Remick SC, Sharma S, Mani S, Ramanathan RK, Doroshow JH, et al. Administration of oxaliplatin to patients with renal dysfunction: a preliminary report of the national cancer institute organ dysfunction working group. Semin Oncol. 2003;30(15):20–5.PubMedCrossRefGoogle Scholar
  51. 51.
    Takimoto CH, Remick SC, Sharma S, Mani S, Ramanathan RK, Doroshow J, et al. Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study. J Clin Oncol. 2003;21(14):2664–72.PubMedCrossRefGoogle Scholar
  52. 52.
    Fakih MG, Padmanabhan A. CEA monitoring in colorectal cancer. What you should know. Oncology. 2006;20(6):579–87.PubMedGoogle Scholar
  53. 53.
    Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol. 2007;25(13):1670–6.PubMedCrossRefGoogle Scholar
  54. 54.
    Goldberg RM, Rothenberg ML, Van CE, Benson AB, III, Blanke CD, Diasio RB, et al. The continuum of care: a paradigm for the management of metastatic colorectal cancer. Oncologist. 2007;12(1):38–50.PubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2008

Authors and Affiliations

  • Herbert J. ZehIII
    • 1
  • Charles K. Brown
    • 1
  • Matthew P. Holtzman
    • 1
  • Merrill J. Egorin
    • 2
    • 3
  • Julianne L. Holleran
    • 2
  • Douglas M. Potter
    • 4
  • David L. Bartlett
    • 1
  1. 1.Division of Surgical Oncology, Department of SurgeryUniversity of Pittsburgh School of MedicinePittsburghUSA
  2. 2.Molecular Therapeutics/Drug Discovery ProgramUniversity of Pittsburgh Cancer InstitutePittsburghUSA
  3. 3.Division of Hematology/Oncology, Department of MedicineUniversity of Pittsburgh School of MedicinePittsburghUSA
  4. 4.Biostatistics Department, Graduate School of Public Health and Biostatistics FacilityUniversity of Pittsburgh Cancer Institute, University of PittsburghPittsburghUSA

Personalised recommendations